Zymeworks Inc (NAS:ZYME)
$ 14.5 0 (0%) Market Cap: 998.72 Mil Enterprise Value: 721.77 Mil PE Ratio: 0 PB Ratio: 2.75 GF Score: 73/100

Zymeworks Inc HERIZON-BTC-01 Top-Line Results Call Transcript

Dec 19, 2022 / 01:00PM GMT
Operator

Thank you for standing by. This is the conference operator. Welcome to Zymeworks HERIZON-BTC-01 Webcasting Conference Call.

(Operator Instructions)

I would now like to turn the conference over to Kenneth Galbraith, Chair and CEO at Zymeworks. Ken, please go ahead.

Kenneth H. Galbraith
Zymeworks Inc. - CEO & Chairman of the Board

Thank you. Hello, everyone, and thanks for joining. My name is Ken Galbraith. I'm the Chair and CEO at Zymeworks. I want to take the time with you today to discuss the positive top-line results for our HERIZON-BTC-01 study. In short order, I'll hand the call over to Dr. Neil Josephson, our Chief Medical Officer as well as Dr. Shubham Pant, who has experience treating patients with zanidatamab in our Phase I and pivotal trials and is also Chairman of the Steering Committee for the HERIZON-BTC-01 study.

All 3 of us will be available for Q&A after the call. Before we begin, I'd like to remind you we'll be making forward-looking statements during this call. Forward-looking statements can be identified

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot